Diversified pharma company running CDMO manufacturing, specialty generics and radiopharmaceuticals under the Jubilant Bhartia Group.
Diversified pharma company running CDMO manufacturing, specialty generics and radiopharmaceuticals under the Jubilant Bhartia Group.
Spread across services and products: its US contract manufacturing, with sterile injectables and allergy products from a Spokane, Washington plant, works for other drug companies, while its radiopharmacy business supplies hospitals with diagnostic isotopes. The group has been working to reduce debt.
In one line: A diversified Indian CDMO/radiopharma conglomerate arm.
Moat: narrow (regulatory licence, process know-how). Radiopharma manufacturing/distribution licences and CDMO plants are difficult and slow to replicate.
Headquarters: Noida, India · Founded: 2020 · Employees: 6,386
Size Jubilant Pharmova (JUBLPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.59B, the 455th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹933.60 on 18 Nov 2026.
Performance Over six months the shares fell 7.7%, against -9.1% for the median peer and +3.8% for the India market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 18.3% over the last twelve months (peer median +6.6%); the operating margin is 6.8% (peer median 12.4%).
Valuation It trades at 29.0× forward earnings against a peer median of 23.8× (6th most expensive of 15).
Capital Return on invested capital runs 8.9 points below its cost of capital (13.4% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹90.1B | ₹82.7B | ₹72.3B | ₹67.0B | ₹62.6B |
| Revenue growth | — | +14% | +8% | +7% | — |
| Gross profit | ₹25.2B | ₹17.3B | ₹16.5B | ₹13.6B | ₹9.81B |
| EBITDA | ₹11.2B | ₹12.1B | ₹10.4B | ₹8.96B | ₹7.61B |
| Net income | ₹2.63B | ₹3.98B | ₹8.39B | ₹771M | -₹610M |
| Free cash flow | n/a | -₹4.36B | -₹2.41B | -₹1.44B | -₹3.78B |
| Capital expenditure | n/a | ₹14.5B | ₹11.2B | ₹8.98B | ₹8.14B |
| Total debt | ₹43.0B | ₹36.1B | ₹27.3B | ₹36.6B | ₹36.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jubilant Pharmova JUBLPHARMA.NS | $1.59B | -8% | +18% | 7% | 29.0× | n/a |
| Piramal Pharma PPLPHARMA.NS | $3.40B | +38% | +9% | 3% | 150.8× | n/a |
| Syngene International SYNGENE.NS | $1.88B | -8% | -6% | 13% | 70.7× | 36.4% |
| Lantheus LNTH | $6.67B | +6% | +2% | 19% | 15.5× | 0.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | JUBLPHARMA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.2% | -4.6% | 7th highest of 21 |
| 6-month return | -7.7% | -9.1% | 10th highest of 20 |
| Distance from 52-week high | -19.7% | -33.2% | 7th highest of 21 |
| Revenue growth (TTM) | +18.3% | +6.6% | 6th highest of 20 |
| Operating margin | 6.8% | 12.4% | 5th lowest of 20 |
| Forward P/E | 29.0× | 23.8× | 6th most expensive of 15 |
| ROIC minus cost of capital | -8.9 pp | +1.2 pp | 5th lowest of 21 |
| EV / EBITDA | 16.1× | 19.8× | 3rd cheapest of 7 |
| Net debt / EBITDA | 2.8× | -1.1× | 3rd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 29.0× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |